Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
KArstic submarine fReshwater Springs (KARST)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Malta
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-09-01
End date: 2024-08-31
Duration (months): 24.0
Total project cost (EUR): 148049.28
EU funding (EUR): 148049.28
Participants: 1
Project status: SIGNED

Submarine groundwater discharge (SGD) is the flow of fresh or recirculated groundwater into the ocean. This process introduces substantial amounts of nutrients to coastal areas, which significantly influences ecological systems. In karstic settings SGD dominantly occurs from submarine springs that manifest as point source discharge sites. Their identification generally relies on sea-surface changes (e.g. visual sea-surface anomalies or changes in sea-surface temperature) and is therefore confined to shallow areas with high discharge rates. As a result the distribution of offshore freshwater springs in karstic environments, which is crucial for determining the architecture and dissemination of offshore groundwater systems, is usually poorly constrained. Similarly, the negative effects of groundwater springs on seagrass diversity and biomass have been investigated at individual springs but have not been characterised over larger areas. This proposal focuses on the identification, characterisation and distribution of submarine springs and their influence on local ecosystems in karstic environments. KARST will make use of state of the art geophysical and remote sensing techniques for optimal imaging at various depths. In the shallow coastal areas (<~5 m), unmanned aerial vehicles equipped with multispectral and thermal infrared cameras will be used to simultaneously image and correlate biological habitats and sea-surface anomalies related to submarine springs. In deeper areas, a newly developed geoelectric system from the University of Kiel in combination with multibeam water column imaging techniques will provide insight into the physical behaviour of the water column as well as salinity and seagrass distribution around springs. All techniques will be guided by biological sampling and flow rate measurements, which will not only help to determine the ecological effects of SGD but will also provide valuable knowledge on the architecture of karstic groundwater systems.

Keywords: submarine groundwater discharge,geoelectric,hydroacoustic,remote sensing,seagrass,submarine spring,karst,hydrogeology,groundwater
The Sound of a Healthy Herd. Revolutionising the Care of Dairy Cattle with Pioneering Acoustic Technology (APT)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Israel
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2019)
Start date: 2020-04-01
End date: 2022-06-30
Duration (months): 27.0
Total project cost (EUR): 3207685.0
EU funding (EUR): 2245379.5
Participants: 1
Project status: CLOSED

Armenta Ltd, was established to address the most-costly disease affecting dairy farming today: Bovine Mastitis. Mastitis is the most pressing disease affecting cows, however antibiotics are the only available option worldwide - close to 50% of antibiotics are used in food producing animals. The continued use of antibiotics in the treatment and prevention of infections of dairy cows has a direct effect on fostering Anti-Microbial Resistance (AMR), an urgent matter of particular public interest. The continued use of antibiotics also weakens the cow’s health, decreasing its milk production and eventually, weak cows are removed from the herd, causing high economic losses that can reach €2.4B per year in Europe alone. Armenta was therefore established to address these pressing economic effects, with a revolutionary way of using APT. Armenta developed innovative non-invasive; antibiotics free therapies based on acoustic pulse technology (APT). APT has been used for over 20 years in human healthcare treating inflammatory diseases. Armenta employs experts in acoustic pulse treatment and engineering, mastitis researchers, ex-dairy farmers and dairy farming operation, bringing their skills and proficiency into developing the optimal solutions for bovine mastitis. Armenta aims at becoming a leader in 1) fighting the spread of AMR 2) boosting the dairy economy giving €1.4B cash back to the EU farmers each year 3) increasing cow’s welfare and longevity. Moreover, it aims at being considered the #1 alternative to antibiotics, endorsed by leading international organization.

Keywords: acoustic pulse therapy,shockwave therapy,clinical and subclinical mastitis,antibiotic free treatment,anti microbial resistance,cow s welfare,increasing farmer s profits,milk quality
Proactive Passenger Flow Management for Airports with an Advanced Forecasting System (AERFOR)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: Germany
Call: Small business innovation research for Transport (H2020-SMEINST-1-2014, 2014)
Start date: 2014-10-01
End date: 2015-02-28
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The worldwide airport passenger volume increased from 2000 to 2014 from 1,6 Billion to over 3,3 Billion passengers and further growth is already predicted. The steady increase of available passenger capacities therefore is one of the most important targets for airports in Europe and worldwide. Ideally this passenger increase can be reached with existing airport infrastructure and without the necessity to invest in new buildings and facitlities. AMORPH.aero is an innovative airport software solution for proactive passenger flow and resource allocation analysis and management by means of advanced forecasting methods. It is build upon Amorph System’s unique OFC-Technology (OFC = Online Forecast) for accurate and fast forecasting of logistic systems. AMORPH.aero’s innovative concept supports in a proactive instead of reactive management of problems in passenger flow. The decision makers can perform “what-if” scenarios, executing validation forecasts before deciding to take a specific measure. AMORPH.aero is operated very successfully at the International Airport in Frankfurt and improved Frankfurt's competitiveness to other airports worldwide significantly. At the beginning of the project the maximum number of passengers was between 54-56 Million per year. Now the maximum capacity is positioned between 62-64 Million per year without investing in new infrastructure. As a next step Amorph Systems plans to market AMORPH.aero to other airports in Europe and worldwide. Airports will gain high advantages by being able to - increase airport capacity with existing infrastructure - reduce required investments in new airport buildings - contribute to environmental targets by optimally using existing airport facilities - enable more efficient resource planning - realize significant cost savings - gaining more satisfied customers

Keywords: proactive passenger flow management,airport management,advanced forecasting,predictive analysis
Oat CHRomosome Evolution and drivers enabling widespread terminal intergenomic translocations in polyploid species (OCHRE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Action type: Marie Skłodowska-Curie actions
Countries involved: United Kingdom
Call: MSCA Special Needs Allowance (H2020-IBA-MSCA-SNLS-2020, 2020)
Start date: 2020-10-29
End date: 2021-10-28
Duration (months): 12.0
Total project cost (EUR): 22250.0
EU funding (EUR): 22250.0
Participants: 1
Project status: CLOSED

Comparative genetic analysis of grasses, one of the most widely distributed plant families and including the three most important human foods, has demonstrated that different groups differ in the evolutionary presence of intergenomic chromosome translocations in polyploid species, including the important crops. The overall goal of our research group is to define the nature and mechanism of terminal intergenomic translocations in oats (Avena) where these are frequent, allowing us to model their contribution to cereal genome evolution. We hypothesize that terminal translocations between oat genomes are related to transposable element activity, a decrease in DNA methylation, and histone modifications that are differential between the genomes. In our main project we proposed a focused series of complementary molecular cytogenetic, bioinformatic, and epigenetic studies on oat and wheat genomes to characterize this physical genome rearrangement process. We will develop translocation-specific probes and find breakpoints using advanced bioinformatic tools. A comprehensive model illustrating the potential mechanisms involved in terminal intergenomic translocations will be elucidated by the simultaneous hybridization with the use of genome- and translocation-specific probes, retrotransposon sequences, and immunostaining. The research will reveal why genomes of oats show frequent intergenomic translocations, playing a significant role in their evolution, in contrast to wheats where the translocations are rare. Bioinformatic analyses for high throughput sequencing data are a huge part of our project. As a disabled person, I need additional support for the purchase of a computer and laptop to perform advanced bioinformatic analyses in the shortest possible time, and thus reduce negative effects of computers on my health. I also apply for monitors with eye care technology, and desk and contour chair adapted to the need of disabled person.

Keywords: evolution,translocations,repetitive dna,retrotransposons,bioinformatics,disabled researcher
Videona: The first Video Social Network for journalist and prosumers allowing them to optimize the generation of quality audio-visual content through mobile phones. (Videona)

Framework: Horizon 2020 — Societal Challenges
Programme: Europe in a changing world - inclusive, innovative and reflective societies
Action type: SME instrument
Countries involved: Spain
Call: New business models for inclusive, innovative and reflective societies (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2017-02-01
End date: 2017-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The number of smartphone users worldwide will be about 1.91 billion in 2015 a figure that will increase another 12.6% to near 2.16 billion in 2016. For the first time, more than one-quarter of the global population used smartphones in 2015 and video capabilities are being improved with every new feature. Videona is created to reach the next level in video mobile applications. Record, edit, share, co-create… four simple things you will like to do as soon as you have the new Videona app in your smartphone. Videona is much more than a application. It will be a Social Video Platform that will enable users with similar profiles or friends in the Videona social network to share in real time, videos they have recorded and edited (semi- or automatically) with their smartphones through the advanced video features of Videona that you can’t find in other apps such as users editing the same video or even use certain parts of that to create a new one turning to be coeditors. The app is mainly addressed to digital natives; young people within 18 to 34 years old. Videona standalone app is currently in the Android market since 7th May, with more than 8000+ downloads and an incredible retention rate of 35% (average in google play is about 5%) in almost 2 months. The app is providing high quality video recording with functionalities to add filters in real-time, flexible use of functions such as flash and front camera, and a basic media editor, that allow music addition to improve the quality of the video and share in that exact moment without loosing the momentum with their smartphones. videona will become the new Video Social Platform that -based in gamification, open licenses for video sharing, high quality recording engine, funny recording filters and effects, powerful, simple and fast video editing and other cutting edge technologies- is enabling users to share in real time high-quality videos they record and edit using their mobile devices.

Keywords: video,collaborative network,audiovisual content,sharing,social,mobile,smartphone,business model,innovation
Scientific Top Training in Antimicrobial Research (AIMMS STAR-PLUS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Co-funding of regional, national and international programmes (COFUND)-Doctoral programmes
Action type: Marie Skłodowska-Curie actions
Countries involved: Belgium,Sweden,Netherlands,Denmark
Call: Marie Skłodowska-Curie Co-funding of regional, national and international programmes (COFUND-DP) (H2020-MSCA-COFUND-2015, 2015)
Start date: 2016-09-01
End date: 2022-12-31
Duration (months): 76.0
Total project cost (EUR): 837120.0
EU funding (EUR): 418560.0
Participants: 6
Project status: CLOSED

The Amsterdam Institute for Molecules, Medicines and Systems (AIMMS, www.aimms.vu.nl) offers an innovative selection procedure for international Top Master's Students to train a new generation of top scientists who can contribute to solving the problem of bacterial, viral and parasitic diseases. A multitude of microbes, and their resistance in particular, threaten the health of European citizens and the community worldwide. For 'attacking' the bugs involved, we need new multidisciplinary approaches and strategies, including translational thinking all the way from molecule to man. This requires the training of a new breed of excellent young scientists, familiar with the whole scope of drug discovery and development, ADME and safety, systems biology, microbiology and molecular biology. The current Dutch NWO AIMMS STAR programme educates these future experts, combining at least two of these fields and the translational context. This enables implementation of state of the art techniques into new strategies and approaches to beat antimicrobial threats, such as the recent Ebola epidemic. With the aid of the proposed MSCA-COFUND, the AIMMS STAR programme can be extended internationally with four additional PhD positions resulting in an established international AIMMS STAR PLUS programme, with a dedicated, open selection procedure for top-talented MSc- / PhD-students from across Europe.

Keywords: antimicrobials,resistance,top training,drug discovery and safety,human health,international,excellence,master s graduate programme
Enriching Market solutions for content Management and publishing with state of the art multimedia Analysis techniques (EMMA)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Innovation actions
Countries involved: Italy,Germany,Greece,Netherlands,United Kingdom
Call: Support technology transfer to the creative industries (H2020-ICT-2016-1, 2016)
Start date: 2017-01-01
End date: 2018-06-30
Duration (months): 18.0
Total project cost (EUR): 981875.0
EU funding (EUR): 780592.0
Participants: 5
Project status: CLOSED

Marketing, PR and communication professionals need tools to support them in the creation of engaging, up-to-date content experiences that their clients can use for establishing meaningful connections to customers and key stakeholders. Creative companies delivering these tools are the main enablers for all new forms of communication we currently experience: from cross-platform content creation to transmedia storytelling. Nowadays with multiple channels, vast amounts of social content, multiple touch points and interactions, constant innovation is required for keeping creative professionals and tools on top of trends and enabling them to deliver. Over the last 10 years, multimedia content analysis has been an exciting research area widely addressed in academia. While initial aspirations and expectations of these new algorithms were not immediately fully met, over the last couple of years the technology has matured a lot, up to a point where it can now be deployed in commercial settings. EMMA will transfer state-of-the art technology in multimedia analysis from the labs to creative industry SMEs, more specifically to solution providers for the media management, branding, marketing and communication. This new technology will enhance existing commercial services, helping SMEs that are active in these sectors to solve current needs of their customers, and thus become more competitive in their market. EMMA focuses on two application areas, tourism and events, addressing the needs of destinations, and events to better drive, connect and engage with audiences. The impact in these vertical markets is huge, since both are among the key industries in Europe. We plan to commercialise the results of EMMA soon after the project end and directly create over 50 jobs in the sixth year of operations.

Keywords: tourism,events
An advanced 3D simulator to generate 3D-personalized tissue and organ models for diagnosis, planning and pre-treatment of medical vascular interventions (MedicalPhant)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-06-01
End date: 2018-09-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

VALIDA INNOVATION S.L. emerged with the goal of developing a new 3D simulator that improves the diagnosis, planning and pre-treatment interventions and therefore, improving patient safety and reduction of associated cost to medical errors. This simulator provides a high value in 3D organ models due to its physical mechanical identical to the real ones are able to replicate the patient´s own organ and pathology. The main objective of MedicalPhant project is to develop and commercialized, based on MRI, ECO and CAT studies on patients, a cardiovascular personalized model of external and internal vasculature that allows simulating complex clinical situations due to cardiovascular diseases are the main cause of death globally. Currently, the simulator prototype has a technology level TRL6 and it has been validated in a relevant environment through its implementation in a real case study of cardiovascular surgery providing diagnostic capacity before intervention and patient´s safety after intervention. However, the company needs to work in the implementation of the business model, in the industrial adaptation of our prototype and, in achieving the certification of our 3D simulator to be commercialized. The key stakeholders involved in this project will be hospitals to carry out clinical trials, private, public hospitals and universities to use our technology, specialized organizations in charge of certificating our device to obtain the CE Mark and FDA, key opinion leaders to get a better penetration on the market and patient associations which will contribute to the dissemination of our innovative 3D printing technology in the cardiovascular market. The initial plan to commercialize the MedicalPhant consists in the combination of own production with a partner plus licensing of the technology. According to our estimation, the cumulative cash flow projected by VALIDA INNOVATION at year 5 will amount €10.3M meaning a ROI of 2.6%.

Keywords: personalized 3d simulator,physical mechanical properties,surgical planning,improvement of diagnosis,training,cardiovascular surgeries
Point of Care Diagnostic Test for the Differential Diagnosis of Inflammatory Bowel Disease (IBDetect)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Estonia
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-12-01
End date: 2020-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Inflammatory bowel disease (IBD) is an umbrella term referring to two hard to diagnose chronic intestinal diseases: ulcerative colitis (UC) and Crohn's disease (CD). IBD is a relapsing condition and diagnosis can be missed if tests are carried out during remission. Thus, the diagnosis of IBD relies on a combination of different tests over a long period. However, for half the patients this results in late diagnosis, a major drawback since often the optimal treatment and management is already affected. Furthermore, IBD diagnosis using current tools (1) can be uncomfortable for patients, (2) carry significant risks including gastrointestinal perforation, and (3) in terms of monetary cost are expensive. Thus, in recent years researchers have been investigating the role of the gut microbiome in IBD, hoping to identify trademark features that could speed up diagnosis and combat the increasing prevalence of IBD in western socities. However, until now the use of this approach has been limited in the field of routine clinical diagnostics due to several limitations. After years of R&D, IPDx has overcome these concerns and introduces IBDetect: the world´s first single test for the differential detection of IBD. It can be used discriminate between the two different types of IBD from a very early, pre-symptomatic stage. All of this can be done in a minimally invasive, cost- and time-effective way with remarkable accuracy. IBDetect can be used to decrease the mean time to diagnosis in UC and CD as well as benefit the optimal treatment and management of these diseases. Our primary target group include gastroenterologists in European hospitals and medical centres in the US. We address the global in vitro diagnostics market in which the IBD-related gastrointestinal diagnostics segment is estimated to reach over €7 billion by 2026. During the Phase 1 study IPDx will conduct a comprehensive feasibility study that includes both technical and commercialisation aspects of the innovation.